Phaseline

Companies › Kiora Pharmaceuticals

Kiora Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KIO-104
Dihydroorotate dehydrogenase (DHODH) inhibitor
DHODHPhase 2Macular EdemaNov 2026
KIO-301
KIO-300 quaternary ammonium salt
–Phase 2Retinitis PigmentosaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06825702KIO-104Phase 2Macular EdemaOphthalmologyNov 2026
NCT06628947KIO-301Phase 2Retinitis PigmentosaOphthalmologyAug 2027

From the company's SEC filings

Cash and short-term investments of $17m on 2026-06-30; operating cash outflow about $10m a year; runway about 20 months at that burn, to Feb 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DHODH (1)

Companies with the same targets

Immunic Jabez Bioscience

Companies built like this

Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.